Patents
US Patent 10,792,232. Methods to deliver antifibrinolytic drugs for anti-aging results. Filed Oct. 17, 2017.
US Patent 11,241,405. Methods and Compositions to Enhance a Non-Surgical Medical Treatment. Filed April 4, 2017.
U.S. Patent 11,413,279. Methods and Compositions for the Antiviral Use of Synthetic Lysine Analogs and Mimetics (Topical use vs HIV lesions)
U.S. Patent 11,576,882. Method to Deliver Anti-Fibrinolytic Drugs to Mitigate Damage to the Brain Caused by Concussive Impact. Filed November 1, 2016.
PCT/US2018/026086. Methods to enhance a non-surgical medical treatment (anti-bruising). Filed April 4, 2018.
PCT/US18/46023. Methods and Compositions for the Antiviral Use of Synthetic Lysine Analogs and Mimetics. Filed August 9, 2018.
PCT/US20/57877. Synergistic Combinations of Synthetic Lysine Analogs, Derivatives, or Mimetics and Pharmaceutical Agents for Enhanced Efficacy of the Pharmaceutical Agents. Filed October 29, 2020.
PCT/2023/016391. Tranexamic Class Arginine and Histidine Mimics as Therapeutic Agents. Filed March 27, 2023.
Multiple patents pending covering methods and compositions for use of lysine analogs and related agents against cancer, microbes, and aging conditions, among other things.
Trademarks
We claim trademark rights in the terms “Tranexamic Lysine”, “Tranexamic Arginine”, “Tranexamic Histidine”, and the “Tranexamic Class Antagonists”.
We also claim trademark rights in the acronyms “TXK”, “TXR”, “TXH”, and “TXCA”.